Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 4/20 | 0.72 |
| ▸ | THRB | P10828 | 2/20 | 0.61 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25633394 | 0.88 | NLRP3 (0.69) | NLRP3THRBRXFP1TP53KMT2A | |
| SCHEMBL25634028 | 0.87 | THRB (0.69) | NLRP3THRBRXFP1MAPTTP53 | |
| SCHEMBL25634032 | 0.86 | THRB (0.71) | NLRP3THRBRXFP1MAPTTP53 | |
| SCHEMBL25633405 | 0.86 | THRB (0.62) | NLRP3THRBMAPTTP53KMT2A | |
| SCHEMBL25634017 | 0.85 | THRB (0.67) | NLRP3THRBRXFP1MAPTTP53 | |
| SCHEMBL25633396 | 0.85 | NLRP3 (0.73) | NLRP3THRBRXFP1TP53 | |
| SCHEMBL25287904 | 0.84 | NLRP3 (1.00) | NLRP3THRBRXFP1MAPTKMT2A | |
| SCHEMBL25771686 | 0.84 | NLRP3 (1.00) | NLRP3THRBRXFP1MAPTKMT2A | |
| SCHEMBL25633347 | 0.80 | THRB (0.51) | NLRP3THRBRXFP1MAPTTP53 | |
| SCHEMBL25771665 | 0.79 | NLRP3 (0.74) | NLRP3THRBTP53KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183249-A1 | NEW TRIAZINOINDOLE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-15 | — | — | US | disclosed |
| US-20230183249-A1 | NEW TRIAZINOINDOLE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183249-A1 | NEW TRIAZINOINDOLE COMPOUNDS | NLRP3, NLRP1, PYCARD | NLRP3 1/4885THRB 277/4885RXFP1 456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.